Management of recurrent non-small cell lung cancer (NSCLC) is a clinical challenge. Around one third of patients who are diagnosed with NSCLC will experience a localregional or advanced stage recurrence. The median time to recurrence from initial diagnosis is 11.5 months. The median age of initial diagnosis of NSCLC is 71 years of age, patients with recurrent disease tend therefore to be even older. Treatment is a challenge, as this elderly patient population tends to have multiple comorbidities, polypharmacy and socioeconomic factors, that have not been accounted for in clinical trials in patients that define our current treatment recommendations. This case-based review outlines some of these challenges and outlines the need for further research.
*For a PDF of the full article, click in the link to the left of this introduction.